RT Journal Article SR Electronic T1 Importation Risk Stratification for COVID19 using Quantitative Serology JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.29.21264323 DO 10.1101/2021.09.29.21264323 A1 David E Williams YR 2021 UL http://medrxiv.org/content/early/2021/10/01/2021.09.29.21264323.abstract AB Recent work (Khoury et al.,Nature Medicine 2021, 27 (7), 1205-1211) has shown that measurement of IgG antibody concentration in blood correlates well with vaccine efficacy. The present communication builds on this work and considers the probability of infection given immunity, taking into account the distribution across the population of antibody concentration in vaccinated or convalescent people. The model is consistent with the observed rates of breakthrough infection following vaccination or previous infection. The model is then developed to consider the use of quantitative measurement of antibody concentration on arrival as an aid to risk stratification of travellers. The model indicates that such a measurement could significantly decrease the quarantine time required to achieve a given level of importation risk.Competing Interest StatementThe author is a founder and shareholder of Orbis Diagnostics Ltd, developing high-throughput quantitative antibody measurement for use at a border as part of an importation risk assessment of travellers.Funding StatementI have received consultancy payments from Orbis DiagnosticsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:none required All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesspreadsheets detailing the calculation available from the author on request